LoVo colon cancer cells resistant to oxaliplatin overexpress c‐MET and VEGFR‐1 and respond to VEGF with dephosphorylation of c‐MET

Oxaliplatin‐resistant LoVo colon cancer cells overexpressing c‐MET and VEGFR‐1 were selected to study several signaling pathways involved in chemoresistance, as well as the effect of increasing amounts of VEGF in the regulation of c‐MET. In comparison with chemosensitive LoVo colon cancer cells, oxaliplatin‐resistant cells (LoVoR) overexpress and phosphorylate c‐MET, upregulate the expression of transmembrane and soluble VEGFR‐1 and, unexpectedly, downregulate VEGF. In addition, LoVoR cells activate other transduction pathways involved in chemoresistance such as Akt, β‐catenin‐TCF4 and E‐cadherin. While c‐MET is phosphorylated in LoVoR cells expressing low levels of VEGF, c‐MET phosphorylation decreases when recombinant VEGF is added into the culture medium. Inhibition of c‐MET by VEGF is mediated by VEGFR‐1, since phosphorylation of c‐MET in the presence of VEGF is restored after silencing VEGFR‐1. Dephosphorylation of c‐MET by VEGF suggests that tumors coexpressing VEGFR‐1 and c‐MET may activate c‐MET as a result of anti‐VEGF therapy. © 2015 Wiley Periodicals, Inc.

[1]  M. Yashiro,et al.  A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma , 2013, British Journal of Cancer.

[2]  J. Bendell,et al.  Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. , 2013, Clinical colorectal cancer.

[3]  S. Szabó,et al.  Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism. , 2013, Biochemical and biophysical research communications.

[4]  I. Berindan‐Neagoe,et al.  Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins , 2013, BMC Genomics.

[5]  Y. Li,et al.  Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma , 2013, Medical Oncology.

[6]  J. Lancaster,et al.  A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth , 2013, Oncology reports.

[7]  H. Seol,et al.  Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. , 2013, Neuro-oncology.

[8]  Hong Wang,et al.  Inhibition of Tcf-4 Induces Apoptosis and Enhances Chemosensitivity of Colon Cancer Cells , 2012, PloS one.

[9]  A. Hecht,et al.  Intrinsic properties of Tcf1 and Tcf4 splice variants determine cell-type-specific Wnt/β-catenin target gene expression , 2012, Nucleic acids research.

[10]  F. Rodriguez,et al.  E-cadherin's dark side: possible role in tumor progression. , 2012, Biochimica et biophysica acta.

[11]  D. Cheresh,et al.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.

[12]  Y. Toiyama,et al.  MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis , 2012, Gut.

[13]  Young Woo Kim,et al.  E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells , 2012, Journal of Cell Science.

[14]  D. Kufe,et al.  MUC1-C Oncoprotein Induces TCF7L2 Transcription Factor Activation and Promotes Cyclin D1 Expression in Human Breast Cancer Cells* , 2012, The Journal of Biological Chemistry.

[15]  T. Deroo,et al.  A Positive Role of Cadherin in Wnt/β-Catenin Signalling during Epithelial-Mesenchymal Transition , 2011, PloS one.

[16]  L. Ellis,et al.  Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration , 2011, British Journal of Cancer.

[17]  Alan Wells,et al.  Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance , 2011, Clinical & Experimental Metastasis.

[18]  J. Christensen,et al.  HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation , 2009, Clinical Cancer Research.

[19]  B. Mezquita,et al.  A novel intracellular isoform of VEGFR‐1 activates Src and promotes cell invasion in MDA‐MB‐231 breast cancer cells , 2010, Journal of cellular biochemistry.

[20]  A. Wong,et al.  c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. , 2010, Neoplasia.

[21]  Robin S. Dothager,et al.  Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant β-Catenin Activation in Colon Cancer , 2009, Clinical Cancer Research.

[22]  T. Sauerbruch,et al.  No functional and transductional significance of specific neuropilin 1 siRNA inhibition in colon carcinoma cell lines lacking VEGF receptor 2. , 2009, Oncology reports.

[23]  Y. Banno,et al.  Sphingosine Kinase Isoforms Regulate Oxaliplatin Sensitivity of Human Colon Cancer Cells through Ceramide Accumulation and Akt Activation* , 2009, Journal of Biological Chemistry.

[24]  E. Rosen,et al.  Role of Src Signal Transduction Pathways in Scatter Factor-mediated Cellular Protection* , 2009, Journal of Biological Chemistry.

[25]  E. Bandrés,et al.  Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer , 2009, Molecular Cancer Therapeutics.

[26]  L. Ellis,et al.  Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells , 2008, Molecular Cancer Therapeutics.

[27]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[29]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[30]  N. Neamati,et al.  Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. , 2006, International journal of oncology.

[31]  D. Kufe,et al.  MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90 , 2006, Oncogene.

[32]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[33]  Jürgen Weitz,et al.  Colorectal cancer , 2005, The Lancet.

[34]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[35]  D. Kufe,et al.  Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. , 2004, Cancer cell.

[36]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[37]  G. Woude,et al.  Hepatocyte growth factor/scatter factor—Met signaling in tumorigenicity and invasion/metastasis , 1996, Journal of Molecular Medicine.

[38]  Lothar Hennighausen,et al.  Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways , 2003, Oncogene.

[39]  P. Houghton,et al.  Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. , 2003, Cancer research.

[40]  中村 誠昌.  E-cadherin-dependent intercellular adhesion enhances chemoresistance , 2003 .

[41]  R. Bachelder,et al.  Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. , 2002, Cancer research.

[42]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Gutkind,et al.  Activation of the Protein Kinase Akt/PKB by the Formation of E-cadherin-mediated Cell-Cell Junctions , 1999, The Journal of Biological Chemistry.

[44]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.

[45]  R. Sharp,et al.  Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Nakamura,et al.  Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. , 1994, Oncogene.